Coronaviruses (CoVs) are a group of positive-sense, single-stranded RNA viruses that cause severe respiratory diseases in a broad range of animal species, including humans.[@b0005], [@b0010], [@b0015] In 2003, one of the novel coronaviruses, severe acute respiratory syndrome CoV (SARS-CoV), caused a total of 8,422 cases of SARS with 916 deaths.[@b0020] The other novel coronavirus, Middle East respiratory syndrome CoV (MERS-CoV), has emerged in April 2012 and posed a serious threat to public health. As of 4 April 2020, a total of 2,494 human MERS-CoV infections with 858 deaths had been reported from 27 countries.[@b0025] Although MERS-CoV can cause primary infections from direct contact with animal reservoirs like camels,[@b0030] person-to-person transmission of this virus has mainly occurred in health-care facilities and family clusters.[@b0035], [@b0040], [@b0045] Recently outbreak of COVID-19, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China and has spread to several other countries.

Drug repositioning for an FDA-approved compound library found that numerous compounds inhibited MERS-CoV infection. However, there are still no approved drugs for coronaviruses.[@b0050] Through high content screening (HCS) platform of Institut Pasteur Korea (IPK) using the Korea Chemical Bank (KCB),[@b0055] we found several novel compounds that can inhibit MERS-CoV infection.[@b0060] We found that *N^4^*-(3-chloro-4-fluorophenyl)-*N^6^*-(3-methoxybenzyl)quinazoline-4,6-diamine **1** was effective for inhibiting MERS-CoV infection. Quinazoline derivatives have previously been reported as potent inhibitors of the protein kinase of epidermal growth factor receptor (EGFR).[@b0065] Most of those compounds were approved as anticancer drugs, including Gefitinib,[@b0070] Lapatinib,[@b0075] Erlotinib,[@b0080] and Afatinib[@b0085]. We thought that quinazoline compounds can exhibit good bioavailability and be easily extended to treatment of MERS-CoV infection. Here we report on the synthesis and biological effects of 4-anilino-6-aminoquinazoline derivatives.

The general synthetic route for 4-aminoquinazoline derivatives is described in [Scheme 1](#f0010){ref-type="fig"} . 2-Amino-5-nitrobenzonitrile was reacted with dimethylformamide-dimethyl acetal (DMF-DMA) in toluene to give (*E*)-*N′*-(2-cyano-4-nitrophenyl)-*N*,*N′*-dimethylformimidamide **2**. *N*,*N*-dimethylformamidine **2** was treated with acetic acid and anilines at 120 °C to produce 6-nitroquinazoline **3**.[@b0090] Reduction of the nitro group of **3** was carried out using iron powder and NH~4~Cl in isopropyl alcohol and water at 100 °C to afford 6-aminoquinazoline **4**. Aromatic amine **4** was reductive alkylated with aldehydes using NaBH(OAc)~3~ and trifluoroacetic acid in isopropyl acetate at 100 °C to give *N*-substituted quinazolines **5**.Scheme 1Synthesis of 6-substituted 4-anilinoquinazoline derivatives. Reagents and conditions: (a) DMF-DMA, toluene, 110 °C, 5 h; (b) ArNH~2~, AcOH, 120 °C, 7 h; (c) Fe, NH~4~Cl, i-PrOH/H~2~O (10/1), 110 °C/4h; (d) Aldehyde, NaBH(OAc)~3~, trifluoroacetic acid, i-PrOAc, 90 °C, 3 h; Acyl chloride, Et~3~N, dichloromethane, rt; or carboxylic acid, EDCI, i-Pr~2~NEt, DMF, rt.

The antiviral activities of the synthesized compounds in Vero cells were determined by immunofluorescence assay (IFA). Vero cells were infected with a korean clinical MERS-CoV isolates and the inhibitory concentration (IC~50~) and cytotoxic concentration (CC~50~) values of the compounds were calculated by nonlinear regression analysis.[@b0055] Molecules with higher selective index (SI) were considered as active molecules ([Fig 1](#f0005){ref-type="fig"} ).Fig. 1Hit against MERS-CoV from a KCB library screen.

Our preliminary structure activity relationship (SAR) studies surrounding **1** were carried out by introducing halide groups on phenyl ring of 4-anilino group ([Table 1](#t0005){ref-type="table"} ). 4-Bromo substituent (**6**) maintained the potency. 4-Fluoro (**7**), 3-chloro (**8**), 4-cyano (**9**), and 3-acetyl (**10**) reduced potency compared to **1**. Interestingly, 4-trifluoromethyl (**11**) can slightly improve the potency. In the next phase optimization, we observed the effects of the substituents of 6 position of quinazoline ring, having fixed with 3-chloro-4-fluoro and 4-trifluoromethyl substituents on phenyl ring at 4 position ([Table 2](#t0010){ref-type="table"} ).Table 1Antiviral effect and toxicity of 4-anilino groups of hit compound **1.**![](fx1_lrg.gif)CompoundYIC~50~(μM)[a](#tblfn1){ref-type="table-fn"}CC~50~(μM)[b](#tblfn1){ref-type="table-fn"}SI[c](#tblfn2){ref-type="table-fn"}**1**3-Cl,4-F5.6\>254.5**6**4-Br7.4\>253.4**7**4-F22.7\>251.1**8**3-Cl\>2523.01.0**9**4-CN\>25\>251.0**10**3-COCH~3~\>25\>251.0**11**4-CF~3~1.8\>251.0[^1][^2]Table 2Structure-Activity Relation of Derivatives of **1** and **11.**![](fx2_lrg.gif)CompoundXR~1~R~2~IC~50~(μM)[a](#tblfn3){ref-type="table-fn"}CC~50~(μM)[b](#tblfn3){ref-type="table-fn"}SI[c](#tblfn4){ref-type="table-fn"}**1**H3-CH~3~O-PhCH~2~H5.6\>254.5**12**H2-CH~3~O-PhCH~2~H3.8\>257**13**H2-OH-PhCH~2~H3.6\>257**14**H3,4-F~2~-PhCH~2~H4.623.05**15**H4-F-PhCH~2~H4.614.43**16**H2-NO~2~-PhCH~2~H3.3\>258**17**H3-NO~2~-PhCH~2~H6.1\>254**18**H4-NO~2~-PhCH~2~H2.7\>258**19**H2-CN-PhCH~2~H\>25\>251**20**H3-CN-PhCH~2~H0.157 ± 0.0023.59 ± 1.125**21**H4-CN-PhCH~2~H4.8\>255**22**H3-H~2~NCO-PhCH~2~H\>25\>251**23**H3-CF~3~-PhCH~2~H2.39.24**24**H*n*-butyl*n*-butyl\>25\>251**25**HcyclohexylH15\>251**26**HCH~3~COH\>25\>251**27**H3-CN-PhCOH\>25\>251**28**H3-CN-*trans*-cynnamoylH\>25\>251**29**OMe3-CN-PhCH~2~H5.813.22**30**OH3-CN-PhCH~2~H\>25\>251**11**H3-CH~3~O-PhCH~2~H1.8\>251**31**H2-CN-PhCH~2~H\>25\>251**32**H3-CN-PhCH~2~H3.6\>257**33**H4-CN-PhCH~2~H4.1\>256**34**H3-NO~2~-PhCH~2~H3.7\>257**35**H4-NO~2~-PhCH~2~H3.3\>258[^3][^4]

First, substituent effects at 6 position of **1** having 3-chloro-4-fluoro aniline at 4 position were evaluated. Changing 3-methoxybenzyl amine to 2-methoxybenzyl amine group **12** showed similar activity (IC~50~ = 3.8 μM). Introducing 2-hydroxybenzyl amine at 6 position of quinazoline ring **13** was tolerated (IC~50~ = 3.6 μM). 3,4-Difluoro (**14**) and 4-fluoro (**15**) compounds gave similar activities (IC~50~ = 4.6 μM). We next explored the effects of electron-withdrawing groups. Compounds with nitro groups (**16** to **18**) showed similar inhibitory effects (IC~50~ = 3.3, 6.1 and 2.7 μM, respectively). Compound with 2-cyanobenzyl amine at 6 position (**19**) showed no inhibitory effect, whereas 4-cyanoebnzyl amine (**21**) functionality was tolerated (IC~50~ = 4.8 μM). Gratifyingly, 3-cyanobenzyl amine analogue **20** resulted in significant higher activity (IC~50~ = 0.157 μM). We tested other electron-withdrawing groups at meta position of benzyl amine substituent. 3-Amidobenzyl amine analogue **22** was detrimental for activity but trifluoromethyl substituent at 3 position **23** retained the inhibitory effect (IC~50~ = 2.3 μM). Then benzyl amine substituents at 6 position were changed to aliphatic amines and amides (**24**--**28**). Aliphatic amine substituents, such as di-*n*-butyl (**24**) and cyclohexyl (**25**), showed little inhibitory effects and amide groups (**26**--**28**) were detrimental. We introduced several substituents at 7 position of **20**. Methoxy at 7 position gave a little decreased activity (**29**, IC~50~ = 5.8 μM) but hydroxy (**30**) showed no inhibitory effects.

The antiviral effects of derivatives at 6 position of **11** with 4-trifluoromethyl aniline group at 4 position were also examined. Most of substituents were well tolerated. 3-Cyanobenzyl (**32**), 4-cyanobenzyl (**33**), 3-nitrobenzyl (**34**) and 4-nitrobenzyl (**35**) showed similar activities (IC~50~ = 3.3 to 4.1 μM) to **11**. However, 2-cyanobenzyl (**31**) substituent exhibited decreased potency.

Considering activity and cytotoxicity, **20** was thought to be the best compounds for anti-MERS drug and evaluated for its hERG, metabolic stability, cytotoxicity ([Table 3](#t0015){ref-type="table"} ). Our optimized lead compound **20** was found to show no hERG binding and have good microsomal stability in both mouse and human. Compound **20** showed no cytotoxicity toward Vero (not infected with MERS-CoV) as well as toward HFL-1, L929 NIH 3 T3 and CHO-K1 cell lines, which shows that potential interaction between compound **20** and viruses might affect the cell viability. The pharmacokinetic parameters of **20** were evaluated in rats by intravenous (i.v.) and oral (p.o.) routes at 2 and 5 mg/kg, respectively ([Table 4](#t0020){ref-type="table"} ). **20** showed reasonable oral bioavailability (21%).Table 3Result of hERG, Microsomal stability, cytotoxicity of **20.**CompoundhERG (μM)MS[a](#tblfn5){ref-type="table-fn"}Cytotoxicity (μM)[b](#tblfn6){ref-type="table-fn"}m[a](#tblfn5){ref-type="table-fn"}h[a](#tblfn5){ref-type="table-fn"}Vero[c](#tblfn7){ref-type="table-fn"}HFL-1L929NIH 3T3CHO-K1**20**\>5060.756.4\>100\>100\>100\>100\>100[^5][^6][^7]Table 4*In vivo* pharmacokinetic profiles in rat of **20.**Parameters[\*](#tblfn8){ref-type="table-fn"}I.V., 2 mg/kgP.O., 5 mg/kgTmax (h)NA[\*\*](#tblfn9){ref-type="table-fn"}2.0Cmax (μg/h)NA0.2T~1/2~ (h)5.95.5AUC (μg·h/mL)1.110.57CL (L/h/kg)1.73NAV~ss~ (L/Kg)6.3NAF~t~ (%)NA21[^8][^9]

In conclusion, we have synthesized a series of 4-anilino-6-aminoquinazoline derivatives and most of the compounds showed anti-MERS-CoV activity in Vero cell. The best compound among the derivatives was **20**, which had the form of quinazoline with 3-Chloro-4-fluoroaniline at 4 position and 3-cyanobenzyl amine at 6 position. Compound **20** showed high anti-MERS-CoV activity (IC~50~ = 0.157 μM, SI = 25) with no cytotoxicity and moderate *in vivo* PK property. Further studies on additional SAR and pharmacological investigation of these compounds are currently underway.
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[^1]: IC~50~ and CC~50~ were derived from the results of at least two dependent experiment in Vero cells infected with MERS-CoV.

[^2]: SI(selective index) = CC~50~/IC~50~ for inhibiting MERS-CoV infection.

[^3]: IC~50~ and CC~50~ were derived from the results of at least two dependent experiment in Vero cells infected with MERS-CoV.

[^4]: SI (selective index) = CC~50~/IC~50~ for inhibiting MERS-CoV infection.

[^5]: \% original compound remained after 30 min incubation.

[^6]: Cell information. Vero: African green monkey kidney cell line, HFL-1: human embryonic lung cell line, L929: NCTC clone 929, mouse fibroblast cell line, NIH 3T3: mouse embryonic fibroblast cell line, CHO-K1: Chinese hamster ovary cell line.

[^7]: Vero cell was not infected with MERS-CoV.

[^8]: All results are the mean of experiments using three rats.

[^9]: NA: not applicable.
